Intranasal steroids are the most effective pharmacologic treatment for seasonal allergic rhinitis (SAR), but they can take several days to take effect, and some patients don't achieve full relief of symptoms. Add-on oral antihistamines or montelukast (Singulair) do not add much benefit.
Bronkiolitis adalah infeksi saluran napas bawah pada bayi yang umumnya disebabkan oleh infeksi Respiratory Syncytial Virus (RSV), ditandai dengan gejala peradangan akut, edema, dan nekrosis dinding sel epitel saluran napas kecil disertai peningkatan produksi mukus. Rendahnya kadar vitamin D turut berperan dalam perkembangan penyakit ini. Gejala dan tanda umumnya dimulai dari batuk dan pilek, da…
A previous meta-analysis suggested that the treatment with erdosteine was associated with significant amelioration of the cumulative global efficacy index and symptoms in comparison to placebo or other mucolytics. However, this conclusion was criticized because the meta-analysis, as it had been done, made it impossible to preclude the potential operation of selection biases within and across t…
Guideline-based management of asthma focuses on disease severity and choosing the appropriate medical therapy to control symptoms and reduce the risk of exacerbations. However, irrespective of asthma severity and often despite optimal medical therapy, patients may experience acute exacerbations of symptoms and a loss of disease control. Asthma exacerbations are most commonly triggered by vir…
Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthmarelated death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combi…
Salmeterol/fluticasone propionate (Seretide/Advair Diskus [dry powder inhaler] or Seretide/Advair inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting b2-adrenoceptor agonist (LABA) plus a corticosteroid. In patients with symptomatic asthma, twice-daily salmeterol/fluticasone propionate maintenance therapy improves lung function and as…
The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate
The efficacy and safety of fluticasone propionate/formoterol fumarate pressurized metered-dose inhaler (pMDI) (fluticasone/formoterol; Flutiform®; 100/10 µg b.i.d.) was compared with fluticasone propionate (Flixotide® Evohaler® pMDI; 100 µg b.i.d.) and fluticasone/salmeterol (Seretide® Evohaler® pMDI; 100/50 µg b.i.d.) in a pediatric asthma population (EudraCT number: 2010-024635-16)
Combination therapies are frequently recommended as maintenance therapy for people with asthma, whose disease is not adequately controlled with inhaled steroids. Fluticasone/salmeterol (FP/SAL) and budesonide/formoterol (BUD/F) have been assessed against their respective monocomponents, but there is a need to compare these two therapies on a head-to-head basis.
Asthma is a common condition due to chronic inflammation of the lower respiratory tract. Chronic lower airway inflammation is known to be more common in individuals that also have inflammatory disorders of the upper airway. The scientific understanding of asthma continues to improve and it is important for providers who treat upper or lower airway inflammation to be familiar with asthma’s def…